top of page
Best-in-Disease Potential in Hepatic & Cardiac Fibrosis
Lead assets, AVB-101 (Gal3 Inhibitor) and AVB-102 (LOXL2 Inhibitor), are oral, Phase 2-ready antifibrotics that will be studied in MASH and cardiomyopathies
Genetically Validated Targets
Mendelian randomization and 25+ human studies tie Gal3 and LOXL2 to MASH and cardiomyopathies
Human Proof-of-Biology
AVB-101 cut ALT 58%, AST 32% and GGT 38% vs. placebo at Day 84 in a Phase 2a hepatic impairment study
Clinical Antifibrotic Activity
AVB-102 reduced biopsy-confirmed collagen fibrosis in 60% of Phase 2 myelofibrosis patients
Derisked Clinical Safety
Highly favorable safety and tolerability profiles across >200 patients dosed with AVB-101 and AVB-102
~10M
US Fibrotic MASH Patients
~3M
US HFpEF Patients
Peak sales opportunity
$2‑4B
Approved Genetic DCM Therapies
Zero
MASH M&A
Novo–Akero up to $5.2B
Roche–89bio up to $3.5B
Patients Dosed Across AVB-101 & AVB-102
>200
bottom of page